Sotera Health Company (SHC) fair value analysis
Nasdaq · Updated 2026-10-19
SHC price how computed
Forward Fair Value verdict
Fairly valuedSHC is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $17.89
- Sector
- Healthcare
- 12-month range
- $13.13–$19.57
- Market cap
- $5.11B
- From 52-week high
- -8.6%
- Shares outstanding
- 285M
- Rank in Healthcare by discount to fair value
- #49 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Sotera Health Company is a provider of sterilization, cleaning, and contamination control solutions for the medical device and pharmaceutical industries. The company operates globally, serving customers across North America, Europe, and other international markets through its network of facilities and service centers.
SHC currently ranks #49 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $5.11B
- P/E (trailing)
- 19x
- Revenue (TTM)
- $1.22B
- Net margin
- 13.4%
- EPS (TTM)
- $0.94
- Gross margin
- 55.4%
- Debt / equity
- 3.41
- Revenue growth (3-yr avg)
- 7.4%
- Shares outstanding
- 285M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $18.67
- 200-day average
- $17.02
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+9.1%)
2026-03 ▲ beat (+5.9%)
2025-12 ▲ beat (+7.3%)
2025-09 ▲ beat (+18.2%)
2025-06 ▲ beat (+17.6%)
2025-03 ▲ beat (+16.7%)
2024-12 ▲ beat (+4.0%)
2024-09 ▼ miss (-5.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 2 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $22.6
- Target vs last price
- +26.3%
What our data shows for SHC
- Our model validated 17 trailing price-to-earnings windows for SHC, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $13.13–$19.57.
- The 14-day relative strength index sits at a neutral 38.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for SHC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent SHC news
TickrTrends' derived news-sentiment signal for SHC is currently leaning positive, computed from recent coverage.
- Sotera Health Announces Third-Quarter 2026 Earnings Release Date (manilatimes.net, 2026-10-21)
TickrTrends take: Sotera Health's announcement of its third-quarter 2026 earnings release date provides an upcoming opportunity for valuation-focused investors to assess whether the company's operational performance supports its current fairly valued status within the Healthcare sector. The earnings report will be critical for determining if recent business developments have altered the fundamental metrics that inform TickrTrends' valuation assessment. Investors should monitor key performance indicators and guidance during that release to evaluate whether SHC's fair value designation remains appropriate or warrants reassessment. - Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers (NASDAQ:SHC) (seekingalpha.com, 2026-09-18)
TickrTrends take: Sotera Health operates in the Healthcare sector with a TickrTrends valuation assessment of Fairly valued. A valuation-focused reader should monitor whether the company's pricing power and recurring revenue streams can sustain growth momentum without requiring significant multiple expansion, as these characteristics typically support more stable cash flows and justify current valuations in the healthcare space. The interplay between pricing dynamics and revenue sustainability will be key to assessing whether the current Fair valuation rating remains appropriate or shifts in either direction. - Here’s Why Sotera Health Company (SHC) Surges 25% in Q2 (finance.yahoo.com, 2026-09-15)
TickrTrends take: Sotera Health Company experienced a 25 percent surge in Q2, which represents a significant positive development for the Healthcare sector company. Given that TickrTrends currently assesses SHC as fairly valued, investors monitoring the stock should observe whether this performance catalyzes a valuation adjustment or if the market has already priced in the improvement. The key consideration for valuation-focused readers is tracking whether the Q2 momentum sustains through coming quarters or faces headwinds that might validate the current fairly valued assessment.
More SHC news
- Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-09)
What people are saying
Follow the SHC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — # SHC Healthcare Sector Update SHC moved from an uptrend to a mixed trend state in the 50/200-day indicator this week. The sector maintains a fairly valued assessment according to current valuation metrics. The shift to mixed trend signals a transition from sustained upward momentum to a more uncertain directional environment.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is SHC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), SHC is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is SHC's TickrTrends verdict?
SHC's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does SHC compare to other Healthcare stocks?
SHC ranks #49 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is SHC overbought or oversold?
SHC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does SHC report earnings next?
SHC's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does SHC usually beat earnings estimates?
Over its last 8 reported quarters SHC beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SHC?
Of 10 analysts covering SHC, 8 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $22.6 (+26.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
SHC vs ALVO · SHC vs EXEL · SHC vs HCSG · SHC vs HSIC · SHC vs IQV